Concepedia

Vicky A. Appleman

VA

Statistics

Publications

10

Citations

705

H-Index

10

Active since

2015

Affiliations

Harvard University(Current)

Tufts University

Dana-Farber Cancer Institute

Takeda (United States)

Beth Israel Deaconess Medical Center

Vicky A. Appleman is an author at Harvard University specializing in oncology, tumor immunology, and immunology.

Publications per year

2015–2023

10

Publications

10

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Helen Y. Zou, Qiuhua Li, Lars D. Engstrom et al. · Proceedings of the National Academy of Sciences · 2015 · 269 citations · Full text

Medicine, Oncology, Pharmacology +15

Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles

Pere Dosta, Alexander M. Cryer, Michelle Z. Dion et al. · Nature Nanotechnology · 2023 · 152 citations

Pharmacy, Pharmaceutics, Pharmacology +14

Activation of Tumor-Cell STING Primes NK-Cell Therapy

Erik H. Knelson, Elena V. Ivanova, Mubin Tarannum et al. · Cancer Immunology Research · 2022 · 88 citations · Full text

Life Sciences, Immunology, Oncology +17

TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies

Elizabeth Carideo Cunniff, Yosuke Sato, Doanh Mai et al. · Cancer Research Communications · 2022 · 55 citations · Full text

Medicine, Immunology, Oncology +17

A PDGFRα-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine

Hyun Jung Jun, Vicky A. Appleman, Hua-Jun Wu et al. · Nature Communications · 2018 · 51 citations · Full text

Medicine, Molecular Biology, Oncology +17

1–5 of 10